Zobrazeno 1 - 10
of 21
pro vyhledávání: ''
Autor:
Shigemasa Takamizawa, Yoshitaka Zenke, Shingo Kitagawa, Taiki Hakozaki, Yasuhiro Kato, Yusuke Okuma
Publikováno v:
Future Oncology. 18:291-300
Background: The efficacy of osimertinib as a first-line treatment for patients with poor performance status (PS) remains unclear. Patients & methods: This multicenter retrospective study evaluated patients treated with osimertinib between 2018 and 20
Publikováno v:
Future Oncology. 17:4249-4261
While survival rates for patients with relapsed/refractory osteosarcoma are low, kinase inhibitors have shown efficacy in its treatment. The multikinase inhibitor lenvatinib, plus ifosfamide and etoposide, showed antitumor activity in a Phase II stud
Autor:
Cornelia Mauch, Oana D. Persa
Publikováno v:
Future Oncology. 17:3809-3817
Background: When patients with advanced melanoma progress after MAPK inhibitor (MAPKI) and immune checkpoint inhibitor (ICI) treatment, they can either undergo chemotherapy or rechallenge with previously used treatments. Methods: The outcomes of 48 p
Publikováno v:
Future Oncology. 17:2475-2488
Aim: This study investigated the association between clinical data and T790M mutation in rebiopsy after EGFR tyrosine kinase inhibitors (EGFR-TKIs) failure, and explored the prognosis of T790M-positive patients. Methods: Patients with non-small-cell
Publikováno v:
Future Oncology. 17:2759-2768
Aim: This study evaluated the effectiveness of lenvatinib monotherapy for first-line treatment of unresectable hepatocellular carcinoma (uHCC) in a real-world setting. Materials & methods: This retrospective cohort study included patients who initiat
Autor:
Junji Lin, Maxine D. Fisher, Lynn McRoy, Mark S. Walker, Cralen Davis, Nan Hu, Debanjali Mitra
Publikováno v:
Future Oncology. 17:1001-1011
Background: Limited studies have evaluated palbociclib-based therapy use in patients with advanced/metastatic breast cancer in the real world. This retrospective study used medical records from US community oncology practices to address the gap. Mate
Autor:
Rickard Sandin, Arlene Reisman, Jean Paty, Yi-Long Wu, Jesus Corral, R. Linke, Seiji Niho, Tony Mok, Maria Rita Migliorino, Adam Pluzanski, Ki Hyeong Lee, Kazuhiko Nakagawa, Xiangdong Zhou, Ying Cheng, Oren Meyers
Publikováno v:
Future Oncology. 17:783-794
Aim: Patient-reported symptoms, functioning and overall quality of life (QoL) were compared between dacomitinib and gefitinib in ARCHER 1050. Patients & methods: Patients (n = 448) with advanced EGFR mutation-positive non-small-cell lung cancer compl
Publikováno v:
Future Oncology. 16:2511-2520
Aim: To evaluate sorafenib treatment in Latin American patients with unresectable hepatocellular carcinoma in the real-world GIDEON study. Patients & methods: Sorafenib administration, safety and efficacy were analyzed by Child–Pugh status. Results
Publikováno v:
Future Oncology. 16:39-47
Until recently, the sole treatment for patients with nonmetastatic renal cell carcinoma (RCC) was nephrectomy followed by observation. As metastatic RCC (mRCC) remains largely incurable (5-year survival rate ∼12%), adjuvant treatment, with potentia
Autor:
Luca Toschi, Sabrina Rossi, Armando Santoro, Pierina Navarria, Vincenzo Di Noia, Fiorenza De Rose, Giovanna Finocchiaro, Davide Franceschini, Giovanni Luca Ceresoli, Marta Scorsetti, Ettore D'Argento, Eleonora Cerchiaro, Maria Bonomi, Giordano D. Beretta
Publikováno v:
Future Oncology. 15:3775-3782
Aim: The association of tyrosine kinase inhibitors (TKIs) and local radiotherapy in EGFR-mutated non-small-cell lung cancer patients experiencing disease progression under TKIs could be a valid an option. Patients & methods: We included 131 patients